Razieh Pouransari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Razieh Pouransari has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
A. Reisjalali
Organ Transplantation Unit, Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publicationA. Salahl
Organ Transplantation Unit, Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publicationA. Torb
Iranian Blood Transfusion Center, Shiraz Branch, Shiraz, Iran
1 shared publicationA.R. Salah
Iranian Blood Transfusion Center, Shiraz Branch, Shiraz, Iran
1 shared publication- Abbas Behzad-Behbahani
Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Ali Bahador
Shiraz Transplant Research Center
1 shared publication
Latest Publications
- 1 February 2025
- Published by Bentham Science Publishers Ltd. in Coronaviruses
- Vol. 6 (1) , 1-8
Comparison of Changes in Liver Function Tests in Pregnant Women with Mild and Severe COVID-19
Objective: Some pregnancies are affected by liver dysfunction, and differentiating them from possible liver dysfunction caused by COVID-19 in pregnancy will lead to a better therapeutic approach and management. Aims: The current study was conducted with the aim of investigating changes in liver function tests (LFTs) in pregnant women with mild and severe COVID-19. Methods: In this retrospective observational study, 130 pregnant women with COVID-19 were examined in two referral hospitals in Iran in 2021-2022. COVID-19 was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) and WHO guidelines. Pregnant women were assigned into two categories of mild and severe COVID-19 based on clinical symptoms and radiologic chest evaluation. Demographic and clinical data of women were recorded. The level of liver enzymes AST, ALT, ALP, total and direct bilirubin was measured in all patients. Fever, oxygen saturation level, preterm delivery, and maternal mortality were reported as final clinical outcomes and compared in two groups. Results: Forty-nine pregnant women with severe COVID-19 and 81 pregnant women with mild COVID-19 were matched in terms of demographic data. The proportion of women with abnormal AST and ALT in the severe COVID-19 group was significantly higher than in the mild group (p< 0.05). However, the proportion of women with abnormal ALP levels in the mild COVID-19 group was significantly higher than in the severe group. Moreover, there was no significant difference between the two groups in terms of the proportion of women with abnormal levels of total and direct bilirubin. Most pregnant women with severe COVID-19 (50%) had a hepatocellular abnormality, while most women with mild COVID-19 (42%) had abnormalities in cholestasis (p=0.003). Conclusion: According to the present findings, liver dysfunction and increased liver enzymes in pregnant women with COVID-19 were related to the severity of the disease, and most women with severe COVID-19 had hepatocellular abnormality, respectively. Therefore, pregnant women with COVID-19 should be closely monitored for LFTs assessment.
- 1 February 2025
- Published by Bentham Science Publishers Ltd. in Coronaviruses
- Vol. 6 (1) , 1-8
Comparison of Changes in Liver Function Tests in Pregnant Women with Mild and Severe COVID-19
Objective: Some pregnancies are affected by liver dysfunction, and differentiating them from possible liver dysfunction caused by COVID-19 in pregnancy will lead to a better therapeutic approach and management. Aims: The current study was conducted with the aim of investigating changes in liver function tests (LFTs) in pregnant women with mild and severe COVID-19. Methods: In this retrospective observational study, 130 pregnant women with COVID-19 were examined in two referral hospitals in Iran in 2021-2022. COVID-19 was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) and WHO guidelines. Pregnant women were assigned into two categories of mild and severe COVID-19 based on clinical symptoms and radiologic chest evaluation. Demographic and clinical data of women were recorded. The level of liver enzymes AST, ALT, ALP, total and direct bilirubin was measured in all patients. Fever, oxygen saturation level, preterm delivery, and maternal mortality were reported as final clinical outcomes and compared in two groups. Results: Forty-nine pregnant women with severe COVID-19 and 81 pregnant women with mild COVID-19 were matched in terms of demographic data. The proportion of women with abnormal AST and ALT in the severe COVID-19 group was significantly higher than in the mild group (p< 0.05). However, the proportion of women with abnormal ALP levels in the mild COVID-19 group was significantly higher than in the severe group. Moreover, there was no significant difference between the two groups in terms of the proportion of women with abnormal levels of total and direct bilirubin. Most pregnant women with severe COVID-19 (50%) had a hepatocellular abnormality, while most women with mild COVID-19 (42%) had abnormalities in cholestasis (p=0.003). Conclusion: According to the present findings, liver dysfunction and increased liver enzymes in pregnant women with COVID-19 were related to the severity of the disease, and most women with severe COVID-19 had hepatocellular abnormality, respectively. Therefore, pregnant women with COVID-19 should be closely monitored for LFTs assessment.
- 1 September 2005
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (7) , 3045-3047
Outcome of Hepatitis B and C Virus Infection on Graft Function After Renal Transplantation
- 1 September 2005
- Published by Elsevier in Transplantation Proceedings
- Vol. 37 (7) , 3045-3047
Outcome of Hepatitis B and C Virus Infection on Graft Function After Renal Transplantation